CancerTherapyAdvisor
@CancerTherAdvsr
Followers
7K
Following
4K
Media
441
Statuses
14K
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.
New York
Joined December 2011
Honored to have chaired this year’s NANETS National Symposium. Great advances in the NET field. Thanks to @CancerTherAdvsr for the coverage of key sessions and our early research of novel nonpeptide conjugate for SSTR positive tumors with @Crinetics #NANETS25 @cityofhope @NANETS1
Read more about these exciting #oncology updates from #NANETS25 with @DanengLi from @cityofhope here: ▶️ https://t.co/cjMokpD2H0
#cancerResearch
0
4
6
Adding a phytochemical-rich food supplement to active surveillance appeared to slow progression of prostate-specific antigen and improve urinary symptoms among men with low-risk #prostatecancer. Published in @EurUrolOncol. https://t.co/3sonRgBpOF
#pcsm
cancertherapyadvisor.com
A phase 2 RCT evaluated progression of prostate-specific antigen and urinary symptoms in men with low-risk prostate cancer who were administered phytochemical-rich food and Lactobacillus probiotic...
0
0
0
Sign up today for our bi-weekly email covering emerging research, conference news, and guideline updates on general oncology, breast cancer and lung cancer: https://t.co/qm14bkAdcv
0
0
0
Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system cancers. Published in @JAMAOnc
https://t.co/K7QPJKPNVs
#gicsm #gicancer #GastricCancerAwaressMonth ##GCAM
cancertherapyadvisor.com
Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and...
0
0
0
Read more about these exciting #oncology updates from #NANETS25 with @DanengLi from @cityofhope here: ▶️ https://t.co/cjMokpD2H0
#cancerResearch
0
1
4
Although the average time to treatment for early-stage breast, cervical, or ovarian #cancer is less than 1 month in many high-income countries, treatment can take 4 months to a year in some low- and middle-income countries. Published in @TheLancet. https://t.co/92OQ4QScFs
cancertherapyadvisor.com
Researchers assessed variations in patterns of care and time to initial treatment for women diagnosed with breast, cervical, or ovarian cancer in various countries.
0
0
0
Phase 3 data from multiple studies presented at #ESMO25 demonstrated that novel staging approaches along with new therapy combinations, such as EV plus pembrolizumab and disitamab vedotin plus toripalimab improved survival outcomes in patients with #bladdercancer.
cancertherapyadvisor.com
ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.
0
0
0
Researchers have identified a pattern of longer OS in patients with stage IV rectal small cell carcinoma than among patients with stage IV colon SCC. Presented at #NANETS25. https://t.co/UyBcM2RuC5
#gicsm
cancertherapyadvisor.com
Researchers have identified a pattern of longer overall survival in patients with stage IV rectal SCC than among patients with stage IV colon SCC.
0
0
0
Looking for a curated list of the top news and updates on lung cancer? Sign up for the Grand Roundup newsletter, delivered to your inbox bi-weekly. https://t.co/qm14bkAdcv
0
0
0
Adjuvant T-DXd can improve outcomes when compared to T-DM1 in patients with high-risk, HER2-positive early #breastcancer who have residual invasive disease. Presented at #ESMO2025. https://t.co/0GwTCbUn7B
#bcsm #ESMO25
cancertherapyadvisor.com
Adjuvant T-DXd can improve outcomes vs T-DM1 in patients with high-risk, HER2+ early breast cancer and residual invasive disease, data suggest.
0
0
0
The risk of #lungcancer varies among responders involved in rescue and recovery after the collapse of the World Trade Center on September 11, 2001. Published in @JAMANetworkOpen. https://t.co/KrkQXM9doh
#lcsm #LCAM #LungCancerAwarenessMonth
0
0
1
CTC levels are an independent prognostic factor for patients with transplant-eligible, newly diagnosed #multipleMyeloma who were treated with a standard-of-care quadruplet regimen. Published in @BloodPortfolio. https://t.co/huOZ3YfPFp
#mmsm
cancertherapyadvisor.com
“We recommend that CTC should be routinely assessed and measured at diagnosis as part of risk evaluation,” study researchers wrote.
0
0
0
Looking for the latest breast cancer research, conference news, and guideline updates? Sign up for the Grand Roundup, our curated and specialized bi-weekly newsletter on clinical topics that matter most to you. https://t.co/qm14bkAdcv
0
0
0
Researchers say they have identified several factors that can be used to better predict the risk of #breastcancer among women. Findings reported in @JAMAOnc. https://t.co/16uB5TX9PM
#bcsm #BCAM #BreastCancerAwarenessMonth
0
0
0
The TROP2 ADC sac-TMT improved survival, compared with platinum-based chemotherapy, in patients with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs. Presented at #ESMO25. https://t.co/nzNeCcmHRh
#lcsm #ESMO2025
cancertherapyadvisor.com
OptiTROP-Lung04 study showed sac-TMT improved survival in pts with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs, compared with chemotherapy.
0
0
1
Adjuvant T-DXd can improve outcomes when compared to T-DM1 in patients with high-risk, HER2-positive early #breastcancer who have residual invasive disease. Presented at #ESMO2025. https://t.co/0GwTCbUn7B
#bcsm #BCAM #BreastCancerAwarenessMonth
cancertherapyadvisor.com
Adjuvant T-DXd can improve outcomes vs T-DM1 in patients with high-risk, HER2+ early breast cancer and residual invasive disease, data suggest.
0
0
0
The association between sedentary time and #breastcancer varies by menopausal status, researchers found. https://t.co/kQX9my8XBk
#bcsm #BCAM #BreastCancerAwarenessMonth
0
0
0
177Lu-edotreotide can improve PFS when compared to everolimus in patients with grade 1-2 GEP-NETs, according to a study presented at #NANETS2025 by @Ja_Capdevila of @VHIO. https://t.co/Bq2CsCGkuQ
2
2
7
PRRT retreatment is well tolerated and confers a survival benefit in patients with well-differentiated, metastatic NETs, according to a study presented at #NANETS2025. https://t.co/L7AMPCEoTV
0
0
0
Searching for the latest news and research about general oncology? Sign up for the Grand Roundup, our curated newsletter to help you stay informed on clinical topics that matter most to you: https://t.co/qm14bkAdcv
0
0
0